The Radioactive Drug Research Committee: Background and retrospective study of reported research data (1975-2004)

Journal of Nuclear Medicine

Volumn 47, Issue 7, 2006, Pages 1220-1226

  Suleiman, Orhan H ^a   Fejka, Richard ^a   Houn, Florence ^a   Walsh, Maria ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Basic science research; Drug quality standards; Food and Drug Administration; PET; Radiation dose limits; Radioactive Drug Research Committee; Radiolabeled drugs

Indexed keywords

CARBON 14; GALLIUM 67; IRON 52; RADIOACTIVE MATERIAL; RADIOISOTOPE; TECHNETIUM 99M; TRITIUM; NEW DRUG; RADIOPHARMACEUTICAL AGENT;

ABSENCE OF SIDE EFFECTS; DATA ANALYSIS; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH CARE POLICY; HUMAN; KNOWLEDGE; MEDICAL LITERATURE; MEDICAL RESEARCH; PEDIATRICS; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; ARTICLE; CLINICAL TRIAL; DRUG APPROVAL; DRUG SCREENING; HUMAN EXPERIMENT; PHARMACY AND THERAPEUTICS COMMITTEE; RADIOTHERAPY; STANDARD; TIME; UNITED STATES;

BIOMEDICAL RESEARCH; CLINICAL TRIALS; DRUG APPROVAL; DRUG EVALUATION; DRUGS, INVESTIGATIONAL; HUMAN EXPERIMENTATION; HUMANS; PHARMACY AND THERAPEUTICS COMMITTEE; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RADIOTHERAPY; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33747145288     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. 44 Federal Register 23193, April 18, 1979.
2. Declaration of Helsinki. World Medical Organization. Br Med J. 1996;313:1448-1449.
3. Code of Federal Regulations Title 21, Part 312. Investigational New Drug Application. April 1, 2005.
4. Code of Federal Regulations Title 21, Part 361.1. Prescription Drugs for Human Use Generally Recognized as Safe and Effective and Not Misbranded: Drugs used in Research. April 1, 2005.
5. Federal Register 27538-27545, July 29, 1974. Radioactive New Drugs: Radioactive Biologics Notice of Proposed Rulemaking.
6. Federal Register 31298-31311, July 25, 1975. Radioactive New Drugs and Radioactive Biologics Termination of Exemptions.
7. Federal Register 19764-19765, April 14, 2005 (Volume 70, Number 71). Draft Guidance for Industry on Exploratory Investigational New Drugs.
8. Federal Register 59569-59572, October 5, 2004 (Volume 69, Number 192). Radioactive Drugs for Certain Research Uses. Public Meeting.
9. Silberstein EB, Saenger EL. Prevalence of adverse reactions to positron emitting radiopharmaceuticals in nuclear medicine. J Nucl Med. 1998;39:2190-2192.
10. Code of Federal Regulations Title 21, Part 50. Protection of Human Subjects Subpart D: Additional Safeguards for Children in Clinical Investigations. April 1, 2005.
11. Wendler D, Belsky L, Thompson KM, Emanuel EJ. Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. JAMA. 2005;294:826-832.
12. Preston DL, Shimuzu Y, Pierce DA, Suyama A, Mabuchi K. Studies of mortality of atomic bomb survivors: report 13 - solid cancer and noncancer mortality: 1950-1997. Radiat Res. 2003;160:381-407.
13. International Commission on Radiological Protection. Recommendations of the International Commission on Radiological Protection: ICRP Publication 26. Ann ICRP. 1977;1(3):1-55.
14. International Commission on Radiological Protection. 1990 Recommendations of the International Commission on Radiological Protection: ICRP Publication 60. Ann ICRP. 1991;21(1-3):1-201.
15. Code of Federal Regulations Title 10, Part 20. Standards for Protection Against Radiation. April 1, 2005.